Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. grew its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 103.1% in the 3rd quarter, HoldingsChannel reports. The firm owned 27,509 shares of the company’s stock after purchasing an additional 13,965 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Ionis Pharmaceuticals were worth $1,800,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in IONS. Allianz Asset Management GmbH acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter worth approximately $752,000. Thrivent Financial for Lutherans acquired a new stake in shares of Ionis Pharmaceuticals in the third quarter valued at $652,000. Victrix Investment Advisors purchased a new position in Ionis Pharmaceuticals in the third quarter valued at $222,000. Lisanti Capital Growth LLC acquired a new position in Ionis Pharmaceuticals during the 3rd quarter worth $6,027,000. Finally, Arizona State Retirement System grew its stake in Ionis Pharmaceuticals by 1.6% during the 3rd quarter. Arizona State Retirement System now owns 44,731 shares of the company’s stock worth $2,926,000 after purchasing an additional 691 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals Stock Up 0.7%

IONS stock opened at $81.15 on Friday. The stock has a market cap of $13.14 billion, a P/E ratio of -33.26 and a beta of 0.29. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96. Ionis Pharmaceuticals, Inc. has a twelve month low of $23.95 and a twelve month high of $86.74. The company’s 50 day moving average is $81.33 and its two-hundred day moving average is $72.12.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Wednesday, February 25th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.18). Ionis Pharmaceuticals had a negative net margin of 40.36% and a negative return on equity of 66.25%. The company had revenue of $203.00 million during the quarter, compared to analysts’ expectations of $156.07 million. During the same period last year, the business earned ($0.66) earnings per share. The company’s quarterly revenue was down 10.6% on a year-over-year basis. Research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on IONS shares. TD Cowen reaffirmed a “buy” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, December 3rd. Bank of America raised their target price on shares of Ionis Pharmaceuticals from $86.00 to $97.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Morgan Stanley set a $95.00 price target on shares of Ionis Pharmaceuticals and gave the stock an “overweight” rating in a report on Wednesday. Leerink Partners raised their price objective on shares of Ionis Pharmaceuticals from $85.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Finally, Piper Sandler lifted their price objective on shares of Ionis Pharmaceuticals from $87.00 to $100.00 and gave the stock an “overweight” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Ionis Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $88.80.

Ionis Pharmaceuticals News Roundup

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Piper Sandler raised its price target to $100 and moved to an “overweight” rating, signaling ~23% upside from current levels — a clear buy-side endorsement. Article Title
• Positive Sentiment: Needham lifted its price target to $103 from $90, another analyst upgrade supporting the rally and reflecting greater confidence in revenue trajectory. Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90
• Positive Sentiment: Updates to Tryngolza outlook are materially positive: recent analysis lifts peak revenue estimates (several sources cite >$2B for Tryngolza and company-level peak revenue/royalty/milestone potential in the multi‑billion range), and management guides to cash-flow breakeven by 2028 — bullish for long-term value. Ionis Pharmaceuticals: Digesting Recent Events
• Neutral Sentiment: Company presented at Oppenheimer’s healthcare conference; slides/transcript provide additional visibility into pipeline progress and commercialization strategy but are informational rather than catalytic. IONS Presents at Oppenheimer Conference Transcript
• Neutral Sentiment: General earnings call coverage/recaps are available for detail on management commentary and guidance; useful for modeling but not single-handedly market-moving. Q4 2025 Earnings Call Summary
• Negative Sentiment: Q4 results were mixed: revenue and Tryngolza sales beat expectations, but EPS missed estimates and management gave a softer 2026 outlook, which pressured the stock in after-hours/early trade. Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook
• Negative Sentiment: Coverage noted the EPS miss led to a gap-down reaction in some sessions; near-term uptake for new drugs and the FY2026 revenue cadence remain the main risk factors to watch. Shares Gap Down on Disappointing Earnings
• Negative Sentiment: Stifel raised its target modestly to $77 but kept a “hold” rating — the lower relative PT signals at least one shop sees limited near-term upside. Article Title

Insider Activity at Ionis Pharmaceuticals

In related news, EVP C Frank Bennett sold 85,089 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $82.93, for a total value of $7,056,430.77. Following the completion of the sale, the executive vice president directly owned 80,293 shares of the company’s stock, valued at $6,658,698.49. This represents a 51.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Shannon L. Devers sold 44,199 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $85.08, for a total value of $3,760,450.92. Following the transaction, the executive vice president owned 17,494 shares in the company, valued at $1,488,389.52. This represents a 71.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 464,579 shares of company stock valued at $37,630,193. Corporate insiders own 2.60% of the company’s stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.